spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  eculizumab 

 HSMN NewsFeed - 15 Oct 2021
Aspaveli(R) (pegcetacoplan) receives positive CHMP opinion for treatment of PNH
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 6 Jul 2015
Strensiq(R) (asfotase alfa) Receives Marketing Approval in Japan for Treatment of Patients with Hypophosphatasia (HPP)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 1 Aug 2014
European Commission Grants Orphan Drug Designation to Soliris(R) (eculizumab) for the Treatment of Patients with Myasthenia Gravis (MG)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 5 May 2014
FDA Approves Conversion of Soliris(R) (eculizumab) Accelerated Approval in aHUS to Regular Approval for the Treatment of Patients with aHUS
Biopharmaceuticals FDA
 HSMN NewsFeed - 13 Sep 2013
Alexion's Soliris(R) (eculizumab) Receives Marketing Approval in Japan for All Patients with aHUS
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 16 Jul 2013
Alexion’s Soliris(R) (eculizumab) Receives Positive Opinion from the Committee for Orphan Medicinal Products for Treatment of Neuromyelitis Optica (NMO)
Biopharmaceuticals Neurology Regulatory
 HSMN NewsFeed - 25 Apr 2013
Alexion Broadens and Strengthens its Executive Leadership Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Nov 2011
Soliris(R) (eculizumab) Granted Marketing Authorization in Europe for Treatment of Patients with Atypical Hemolytic Uremic Syndrome (aHUS)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 7 Apr 2011
Alexion Submits Applications for Soliris(R) (Eculizumab) as a Treatment for Patients with Atypical Hemolytic Uremic Syndrome (aHUS) in the United States and European Union
Biopharmaceuticals
 HSMN NewsFeed - 30 Nov 2010
Seattle Genetics Announces Additions to Commercial Leadership Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Apr 2010
Alexion's Soliris(R) (Eculizumab) Receives Marketing Approval in Japan for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 1 Dec 2009
Alexion Appoints William R. Keller to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Apr 2009
Alexion Submits NDA in Japan for Soliris(R) (eculizumab) as a Treatment for Patients with PNH
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 6 May 2008
Rib-X Pharmaceuticals, Inc. Appoints Nancy Motola as Senior Vice President of Regulatory Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Apr 2008
Transdel Pharmaceuticals Appoints Chief Medical Officer and Chief Operating Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Mar 2008
Alexion Completes Enrollment in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
 HSMN NewsFeed - 14 Feb 2008
Alexion Acquires All Rights to OMRF Patents Related to Soliris(R)
Biopharmaceuticals
 HSMN NewsFeed - 11 Dec 2007
PNH Patients With Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion Support Have Significant Disease Burden; Soliris(R) Therapy Provided Clinical Improvements in PNH Patients Regardless of Disease Severity
Biopharmaceuticals
 HSMN NewsFeed - 10 Dec 2007
Long-Term Soliris(R) Therapy Improved or Stabilized Kidney Function in Patients With PNH
Biopharmaceuticals
 HSMN NewsFeed - 4 Dec 2007
Soliris(R) Demonstrates Reductions in Hemolysis and Improvements in Fatigue, Overall Quality of Life and Anemia in a Broad Population of PNH Patients
Biopharmaceuticals
 HSMN NewsFeed - 20 Aug 2007
PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
Biopharmaceuticals
 HSMN NewsFeed - 22 Jun 2007
Alexion's Soliris(TM) Granted Marketing Approval in Europe for Treatment of All Patients With PNH
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 11 Jun 2007
Studies Show Efficacy and Safety of Alexion's Soliris(TM) in Broad Population of PNH Patients
Biopharmaceuticals
 HSMN NewsFeed - 4 Jun 2007
Soliris(TM) Effective in PNH Patients With History of Aplastic Anemia and Myelodysplastic Syndromes
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Apr 2007
CHMP Adopts Positive Opinion for Alexion's Soliris(TM) in Europe
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 19 Mar 2007
Update: FDA Approves Alexion's Soliris(TM) for All Patients With PNH
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 Mar 2007
FDA Approves Alexion's Soliris(TM) for All Patients With PNH
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 Dec 2006
Eculizumab is Well Tolerated and Demonstrates Significant Improvement During 52 Weeks of Treatment in Open-Label Phase III SHEPHERD Study in PNH Patients
Biopharmaceuticals
 HSMN NewsFeed - 14 Nov 2006
FDA Grants Priority Review for Soliris(TM) (eculizumab) BLA for Treatment of Paroxysmal Nocturnal Hemoglobinuria
Biopharmaceuticals FDA
 HSMN NewsFeed - 26 Sep 2006
Alexion Submits Market Authorization Application for Soliris(TM) (eculizumab) in the Treatment of Paroxysmal Nocturnal Hemoglobinuria to the European Medicines Agency
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 13 Jul 2006
Alexion Pharmaceuticals Purchases Biopharmaceutical Manufacturing Site in Rhode Island
Biopharmaceuticals
 HSMN NewsFeed - 6 Jul 2006
Alexion Pharmaceuticals Appoints David L. Hallal Vice President U.S. Commercial Operations
Biopharmaceuticals Personnel
Return to NewsFeed  

 Additional items found! 32

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 32 additional stories matching:
eculizumab
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.